These advanced pan-KRAS-mutant NSCLC patients (n = 29) who received anlotinib monotherapy had a total objective response rate (ORR) of 27.6%, a median progression-free survival (PFS) of 127 days, and a median overall survival (OS) of 240 days (Supplementary Fig. 3b-d). Here, KRAS is linked to non-small cell lung carcinoma.